Symbol="FATE"
AssetType="Common Stock"
Name="Fate Therapeutics Inc"
Description="Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is headquartered in San Diego, California."
CIK="1434316"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="465359000"
EBITDA="-247323008"
PERatio="None"
PEGRatio="0"
BookValue="4.863"
DividendPerShare="0"
DividendYield="0"
EPS="-2.33"
RevenuePerShareTTM="1.407"
ProfitMargin="-1.716"
OperatingMarginTTM="-1.918"
ReturnOnAssetsTTM="-0.22"
ReturnOnEquityTTM="-0.423"
RevenueTTM="136866000"
GrossProfitTTM="-224154000"
DilutedEPSTTM="-2.33"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="2.203"
AnalystTargetPrice="8.16"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="20.01"
PriceToBookRatio="2.883"
EVToRevenue="15.93"
EVToEBITDA="-3.697"
Beta="1.483"
num_52WeekHigh="37.13"
num_52WeekLow="4.02"
num_50DayMovingAverage="5.21"
num_200DayMovingAverage="10.16"
SharesOutstanding="98384000"
DividendDate="None"
ExDividendDate="None"
symbol="FATE"
open="4.75"
high="4.88"
low="4.65"
price="4.66"
volume="2130794.00"
latest_trading_day="2023-07-17"
previous_close="4.73"
change="-0.07"
change_percent="-1.4799%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="98"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="2"
Volume_recent_avg="2553142"
Change_recent_avg="-0.02"
Delta_recent_avg="0.36"
Variance_recent_avg="0.18"
Change_ratio_recent_avg="-0.49"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="2"
Aroon_momentum_negative="98"
image_negative_thumbnail_id_1="127"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0049.jpeg"
image_negative_thumbnail_id_2="503"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0102.jpeg"
image_neutral_thumbnail_id_1="582"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0017.jpeg"
image_neutral_thumbnail_id_2="563"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0036.jpeg"
image_positive_thumbnail_id_1="680"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0028.jpeg"
image_positive_thumbnail_id_2="623"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0085.jpeg"
image_professor_thumbnail_id_1="1194"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0028.jpeg"
image_professor_thumbnail_id_2="1177"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0011.jpeg"
